NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.31 by $0.80. The biopharmaceutical company had revenue of $294.45 million for the quarter, compared to analysts' expectations of $12 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The business's revenue was up 4124.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.26) EPS. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals.

6 brokers have issued 12 month price targets for Lexicon Pharmaceuticals' shares. Their forecasts range from $3.00 to $17.00. On average, they expect Lexicon Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 152.7% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

News stories about LXRX stock have been trending neutral recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 14,520,000 shares, an increase of 6.9% from the January 15th total of 13,580,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is currently 10.5 days. Approximately 14.1% of the shares of the stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Progenics Pharmaceuticals (PGNX), Geron (GERN), Novavax (NVAX), Orexigen Therapeutics (OREX) and Iovance Biotherapeutics (IOVA).

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (11.82%), Boxer Capital LLC (2.61%), Renaissance Technologies LLC (1.13%), State Street Corp (0.84%), Marshall Wace LLP (0.80%) and Bank of New York Mellon Corp (0.75%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jacobs Levy Equity Management Inc., Bank of America Corp DE, Pinnacle Associates Ltd., State Street Corp, Jane Street Group LLC, Goldman Sachs Group Inc. and Wedbush Securities Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

LXRX stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of New York Mellon Corp, AQR Capital Management LLC, Renaissance Technologies LLC, Oxford Asset Management LLP, Spark Investment Management LLC, Boxer Capital LLC and Barrow Hanley Mewhinney & Strauss LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $2.77.

Lexicon Pharmaceuticals has a market capitalization of $294.37 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.